Connect with us

Technology

LIGHT AI ACHIEVES ISO 13485 AND MDSAP CERTIFICATION, ADVANCING REGULATORY READINESS FOR HEALTH CANADA SUBMISSION OF QUICKSCAN™ SOFTWARE PLATFORM

Published

on

Quality Management System Certification Marks Key Regulatory Milestone for Light AI’s Software as a Medical Device Platform

VANCOUVER, BC, June 29, 2026 /CNW/ – Light AI Inc. (“Light AI” or the “Company”) (CBOE CA: ALGO) (FSE: OHC) (OTCQB: OHCFF) an artificial intelligence health technology company developing Software as a Medical Device (“SaMD”) solutions, is pleased to announce that it has successfully completed its Quality Management System”” audit and has been certified as being in conformity with ISO 13485:2016 and the Medical Device Single Audit Program (“MDSAP”) by Intertek.

The MDSAP certification confirms that Light AI’s quality management system meets internationally recognized standards for the design, development, manufacture, and distribution of AI/ML powered devices used to screen, monitor, and assist in the detection of ENT infections management of medical devices and Software as a Medical Device technologies for Canada, the United States and Australia.

Achievement of MDSAP and ISO 13485 certification represents a significant regulatory milestone for the Company and supports its planned regulatory submissions for its QuickScan™ and QuickScan™ Strep A software platforms in Canada.

The certification covers the Company’s quality management processes associated with the development of QuickScan™ software-based medical technologies and establishes the operational framework required to support ongoing regulatory, clinical, and commercialization activities.

“As we continue executing our regulatory strategy, achieving MDSAP and ISO 13485 certification is an important accomplishment for Light AI,” said John R. Luna, Chief Executive Officer of Light AI. “This certification demonstrates our commitment to maintaining a robust medical device quality management system and reflects the significant work completed by our team to align our operations with internationally recognized medical device standards. With this milestone achieved, we are positioned to advance our planned Health Canada regulatory submissions for QuickScan™ Strep A.”

The Company’s QuickScan™ Strep A platform is being developed as Software as a Medical Device solutions intended to support healthcare professionals in the assessment of patients presenting with symptoms consistent with pharyngitis and potential Group A Streptococcus (“Strep A”) infection.

MDSAP allows recognized auditing organizations to conduct a single regulatory audit of a medical device manufacturer’s quality management system that satisfies the requirements of multiple participating regulatory jurisdictions including Canada, Australia and the United States. ISO 13485 is the internationally recognized quality management standard specific to the medical device industry and is widely utilized by regulators and manufacturers globally.

Light AI believes that completion of its MDSAP and ISO 13485 certification establishes an important foundation for future regulatory submissions, including the Company’s planned Health Canada Medical Device License application for QuickScan™ Strep A.

The Company will continue to advance its regulatory, clinical validation, and commercialization activities and expects to provide updates regarding Health Canada submission timing and other key milestones as appropriate.

About Light AI Inc. (CBOE CA: ALGO / FSE: OHC / OTCQB: OHCFF)

Light AI Inc. is a technology company focused on developing artificial intelligence health screening and diagnostic solutions. Light AI QuickScan™ is a technology platform which represents the next generation of patient management: it applies AI algorithms to compatible smart device images, starting with images of Strep A and anticipated expansion with other medical conditions, to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind as its computing platform includes the 4.5 billion smartphones that exist in the world today. Light AI is at the forefront of developing innovative screening and diagnostic solutions aimed at improving healthcare delivery worldwide. Their cutting-edge AI powered technology offers rapid, accurate, and cost-effective screening and diagnostic tools designed to address critical healthcare challenges.

In pre-FDA validation studies, Light AI’s algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus (GAS). The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease (RHD), which imposes a global economic burden exceeding $1 trillion annually. Light AI’s technology offers a significant advancement in the accurate and timely identification of GAS pharyngitis, potentially reducing the incidence of RHD and its associated costs. Light AI’s approach to applying AI to smart device images can be expanded to other medical conditions, as well as other areas of analysis. Light AI’s vision is to combine the Light AI QuickScan™ software platform with AI in-the-Cloud to create a Digital Clinical Lab that provides quick and accessible diagnosis for countless conditions that today require expensive and time-consuming imaging or lab processes.

ON BEHALF OF THE COMPANY

“John R. Luna”
Chief Executive Officer
Telephone: 1-(888) 804-9459
Email: jluna@light.ai

Website: https://light.ai/
LinkedIn: LinkedIn/company/Light AI 
X (Formerly Twitter): @lightaihealth

Forward-Looking Information:

This news release contains statements and information that, to the extent that they are not historical fact, constitute “forward-looking information” within the meaning of applicable securities legislation, including statements relating to its anticipated regulatory submissions for the Company’s QuickScan™ and QuickScan™ Strep A software platforms in Canada; the Company’s business plan; and QuickScan™ Strep A platform being developed as Software as a Medical Device solutions and that it will support healthcare professionals in the assessment of patients. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, but not limited to, statements relating to the Company’s financial performance, business development, results of operations, and those listed in filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking information to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws.

SOURCE Light AI Inc.

Continue Reading

Technology

Epson to Showcase Collaborative 6-Axis Robot and Integrated Automation Solutions at The ASSEMBLY Show 2026

Published

on

By

AX6 Cobot and Live Demonstrations Highlight Epson’s Expanding Automation Portfolio

LOS ALAMITOS, Calif., Oct. 21, 2026 /PRNewswire/ — Epson Robots, the #1 SCARA robot manufacturer in the world, will showcase its expanding automation portfolio, including its first collaborative robot, the AX6, at The ASSEMBLY Show 2026, taking place in Rosemont, Illinois from Oct. 27-29, 2026, in booth #331.

Epson to Showcase AX6 Cobot and Integrated Automation Solutions with Live Demos at The ASSEMBLY Show 2026

“Every automation application has different safety requirements, and there is no one-size-fits-all approach,” said Scott Marsic, group product manager, Epson Robots. “With the AX6 and SafeSenseTM technology, Epson is giving manufacturers more options to select the right solution for their requirements. At The ASSEMBLY Show, we look forward to demonstrating how these offerings complement our broader robotics portfolio and help manufacturers address a wide range of automation needs.”

With Epson’s latest automation technologies, attendees can experience live demonstrations showcasing integrated robotics, vision, and feeding solutions. The live applications will highlight practical, cost-effective solutions for real-world production environments. An educational speaking session will also focus on selecting the right automation approach for each application. Epson highlights at The ASSEMBLY Show 2026 will include:

Speaking Engagement”Automation Isn’t the Answer. Choosing the Right Automation Is.” – Marsic will outline a practical framework for choosing the right automation strategy, from evaluating opportunities and avoiding application creep to balancing critical design considerations such as safety, robot geometry, workcell design and flexibility. The session will focus on solving the right business problem to create automation systems that are easier to implement, scale and maintain while delivering stronger productivity, reliability and long-term ROI. The session will take place Wednesday, October 28 from 2 – 2:30 p.m. at the Learning Theater.AX6 Collaborative 6-Axis Robot – See Epson’s first collaborative robot in action, featuring a lightweight, compact footprint and intuitive no-code software designed to simplify programming and deployment. Power- and force-limiting capabilities and flexible end-of-arm options support collaborative applications where space, ease of use and fast redeployment are priorities.SafeSense Interactive Demo – Experience a hands-on demonstration of Epson’s SafeSense technology, which uses sensors to detect when a person enters the robot’s workspace, supporting safe human-robot interaction while maintaining high-performance automation.IntelliFlexTM Feeding System – See live demonstrations featuring Epson’s latest SCARA and 6-Axis robots integrated with IntelliFlex Feeding Systems for automated part handling and assembly applications.Epson RC+® Development Software – Explore Epson’s PC-based environment with intuitive GUI Builder for custom interfaces along with integrated vision and IntelliFlex capabilities. Developed and supported by Epson, the software is designed to simplify automation development and deployment.

The ASSEMBLY Show 2026 will take place on Oct. 27 from 4 p.m. to 7 p.m. CDT, Oct. 28 from 10 a.m. to 5 p.m. CDT and Oct. 29 from 9 a.m. to 2 p.m. CDT at the Donald E. Stephens Convention Center in Rosemont, Illinois. To learn more about Epson robot solutions at the show, stop by booth #331 or visit www.epsonrobots.com to contact a robot expert.

About Epson Robots

Epson Robots is a global leader in PC-controlled precision factory automation, with well over 250,000 units sold worldwide1 and a product line of hundreds of models of easy-to-use SCARA and 6-Axis robots based on a common PC-based platform. Building on four decades of experience, Epson Robots delivers robots for precision assembly and material handling applications in the aerospace, appliance, automotive, biotechnology, consumer product, electronics, food processing, medical device, pharmaceutical, plastics, semiconductor, and telecommunication industries. For more information, visit www.epsonrobots.com.

About Epson

Epson is a technology innovation and engineering company whose philosophy of efficient, compact and precise innovation enriches lives and helps create a better world. The company uses technology and engineering ability to implement real-world solutions in precision innovation, industrial and robotics, office and home printing, and visual and lifestyle.

Led by the Japan-based Seiko Epson Corporation, the worldwide Epson Group generates annual sales of more than JPY 1.4 trillion. corporate.epson/en/

Epson America, Inc., based in Los Alamitos, Calif., is Epson’s regional headquarters for the U.S., Canada and Latin America. To learn more about Epson, please visit: epson.com. You may also connect with Epson America on Facebook (facebook.com/Epson), X (x.com/EpsonAmerica), YouTube (youtube.com/epsonamerica) and Instagram (instagram.com/EpsonAmerica).

1 Epson internal sales data through April 2026.

EPSON and Epson RC+ are registered trademarks of Seiko Epson Corporation. SafeSense and IntelliFlex are trademarks of Epson America, Inc. All other product and brand names are trademarks and/or registered trademarks of their respective companies. Epson disclaims any and all rights in these marks. Copyright 2026 Epson America, Inc.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/epson-to-showcase-collaborative-6-axis-robot-and-integrated-automation-solutions-at-the-assembly-show-2026-302915812.html

SOURCE Epson America, Inc.

Continue Reading

Technology

Limber Health Launches Recovery Forecast, the First-Ever Predicted Outcomes Solution for Rehab Therapy

Published

on

By

Built on the largest risk-adjusted patient outcomes database in rehab therapy, Limber’s Recovery Forecast replaces traditional single point-in-time forecasts or MCID comparisons with a 90-day outlook

PITTSBURGH, Oct. 21, 2026 /PRNewswire/ — Limber Health, a Net Health company, today announced Recovery Forecast, the first-ever predicted outcomes trajectory solution for rehab therapy. Built into the Limber outcomes platform, Recovery Forecast maps each patient’s expected path throughout care by comparing them with millions of completed assessments and applying robust risk adjustment. Available to clients this fall, this new clinical capability covers the primary MSK regions of injury.

“Current solutions show a point-in-time measurement, but rarely provide context or insight into the score,” said Nirav Modi, president of Limber Health. “Recovery Forecast shows clinicians how a patient is progressing through their plan of care, so they can assess, adjust, and guide them toward the best possible improvement.”

Because Limber Outcomes follows patients from evaluation through the full episode of care, the expected path stays visible between visits. At intake, the feature predicts each patient’s path; then at each reassessment, clinicians compare the actual score with the prediction for real-time context. This gives clinicians an opportunity to adjust the course of care.

“Being able to predict a patient’s outcome trajectory is a game changer,” said Brian Kelly, Vice President of Innovation & Clinical Excellence at Ivy Health. “It transforms outcomes data into real-time clinical intelligence that enhances patient engagement, empowers proactive clinical decision-making, and ensures every patient is positioned for an optimal recovery.”

A newly developed progression indicator, the Predicted Moderate Clinical Improvement (P-MCI), marks where a patient is expected to reach clinically meaningful improvement. P-MCI is already part of commercial payer quality programs. It underpins five functional improvement measures in the CMS proposed rule for the 2027 Physician Fee Schedule, with Limber Health and Patient360 as measure stewards. For more information about Limber Recovery Forecast, click here. 

About Limber Health

Limber Health, a Net Health company, extends in-person musculoskeletal (MSK) care into the home with Remote Therapeutic Monitoring (RTM), Home Exercise Programs (HEP), and Limber Outcomes, which helps practices measure patient progress and predict recovery using the largest risk-adjusted patient outcomes database in rehab therapy. Limber’s solutions are developed by physical therapists and physicians. Learn more at www.limberhealth.com.

About Net Health

For over 30 years, Net Health has gathered specialty knowledge shaped by human expertise and informed by patient outcomes. Today, this depth of knowledge is the foundation for an AI-native specialty platform that delivers intelligence to clinicians across the care continuum, enabling them to be present with patients during the moments that matter. Net Health is a trusted source of specialty solutions for more than 34,000 healthcare organizations, and is a portfolio company of The Carlyle Group, Level Equity, and Silversmith Capital Partners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/limber-health-launches-recovery-forecast-the-first-ever-predicted-outcomes-solution-for-rehab-therapy-302915819.html

SOURCE Net Health Systems, Inc.

Continue Reading

Technology

Asuri.ai Launches Multi-Agent AI Platform for Persistent Business Workflows

Published

on

By

The agentic platform helps nontechnical teams save time, eliminate redundant work and deploy specialized AI agents across more than 1,000 existing applications

IRVINE, Calif., Oct. 21, 2026 /PRNewswire/ — Asuri today announced the launch of its multi-agent enterprise AI platform, designed to help businesses move beyond copilots and deploy persistent AI workflows across complete business processes.

As AI models become more capable, the challenge for businesses is shifting from generating answers to safely giving AI the context, system access and autonomy required to perform real work.

Asuri brings those pieces into one platform.

Nontechnical teams can define a business process, connect the applications involved, assign specialized agents to different responsibilities, and control what each agent can access, recommend or execute. By coordinating work that would otherwise require employees to repeatedly move between systems, gather information and perform routine follow-ups, Asuri helps organizations save time and remove redundant manual work.

“The model itself is becoming less of the bottleneck,” said Artem Bespaloff, CEO and co-founder of Asuri. “The harder problem is coordinating agents across real business systems while giving each one the right context, permissions and level of autonomy.”

Unlike traditional AI assistants that primarily respond to prompts, Asuri is designed around persistent multi-agent workflows.

Asuri combines multi-agent orchestration, workflow logic, persistent context and agent-level permission controls in a single environment, with more than 1,000 integrations connecting agents to the software businesses already use.

This allows companies to automate processes across existing systems instead of replacing their technology stack, reducing repetitive administrative work and freeing employees to focus on higher-value decisions and relationships.

As part of its launch, Asuri is introducing prebuilt customer intelligence workflows that consolidate information from multiple business systems, analyze client activity against company-defined rules, and automatically alert employees to significant developments. By eliminating the need to manually track client activity across different platforms, these workflows reduce the workload on sales and research teams, helping them stay informed, identify opportunities, and focus on higher-value activities.

The same architecture can support workflows across sales, operations, finance, customer success, research and internal compliance.

Businesses can learn more and request access at Asuri.ai.

About Asuri

Asuri is a multi-agent enterprise AI platform, built by Sprouter Technologies, for persistent, governed business workflows. With more than 1,000 integrations, Asuri helps organizations connect specialized AI agents across their existing applications, reduce repetitive work, save employee time and automate processes while maintaining individual permissions, autonomy boundaries and human oversight.

For more information you can contact team@asuri.ai

View original content to download multimedia:https://www.prnewswire.com/news-releases/asuriai-launches-multi-agent-ai-platform-for-persistent-business-workflows-302915829.html

SOURCE Sprouter Technologies

Continue Reading

Trending